BLyS expression by GC follicular T cells is required for the efficient selection of high-affinity GC B cells.

This study reveals that successful therapeutic targeting of the CD47-SIRPα axis in peripheral T-cell lymphoma is highly dependent on the Fc-FcγR interaction and is augmented by cotreatment with the anti-CCR4–targeted monoclonal antibody mogamulizumab.

In this study, a 5.9-inch foldable Book-Type AMOLED display was developed. A folding test was performed repeatedly. The display survived the folding test (100,000 folds) with a curvature radius of 2 mm.

A folding screen type OLED display was developed (Fig. 1) to demonstrate the application of a flexible display. The display surface can be bent with a curvature radius of 4 mm. To protect an OLED against moisture, inorganic passivation layers are provided on the upper and lower sides of the flexible display. Using our transfer technology, dense passivation layers can be obtained. The measured water vapor transmission rate of the layer is 7 10 6 g/m 2 day or less, which improves OLED reliability.

CPX-351 and venetoclax and azacitidine (ven/aza) are both indicated as initial therapy for acute myeloid leukemia (AML) in older adults. In the absence of prospective randomized comparisons of these regimens, we used retrospective observational data to evaluate various outcomes for patients with newly diagnosed AML receiving either CPX-351 (n=217) or ven/aza (n=439). This study used both a nationwide electronic health record (EHR)-derived de-identified database and the University of Pennsylvania EHR. Our study includes 217 patients who received CPX-351 and 439 who received venetoclax/azacitidine. Ven/aza patients were older, more likely to be treated in the community, and more likely to have a diagnosis of de novo AML. Other baseline covariates were not statistically significantly different between the groups. Median overall survival (OS) for all patients was 12 months and did not differ based upon therapy (13 months for CPX-351 versus 11 months for ven/aza, HR 0.88, 95% CI 0.71-1.08, p = 0.22). Overall survival was similar across multiple sensitivity analyses. Regarding safety outcomes, early mortality was similar (10% vs. 13% at 60 days). However, documented infections were higher with CPX-351 as were rates of febrile neutropenia. Hospital length of stay, including any admission prior to next cycle of therapy, was more than twice as long for CPX-351. In this large multi-center real word dataset, there was no statistically significant difference in OS. Prospective randomized studies with careful attention to side effects, quality of life, and impact on transplant outcomes are needed in these populations.